" class="no-js "lang="en-US"> Enterprise Therapeutics - Medtech Alert
Wednesday, September 03, 2025
Enterprise Therapeutics | Pharmtech Focus

Enterprise Therapeutics

About Enterprise Therapeutics

Enterprise Therapeutics

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.

In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

The leadership team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. The company benefits from a close working relationship with the School of Life Sciences at the University of Sussex.

Related Story

Enterprise Therapeutics Appoints Dr Niyati Prasad as Chief Medical Officer

February 9 2022

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel […]